EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

  1. Rosenberg, J.E.
  2. Powles, T.
  3. Sonpavde, G.P.
  4. Loriot, Y.
  5. Duran, I.
  6. Lee, J.-L.
  7. Matsubara, N.
  8. Vulsteke, C.
  9. Castellano, D.
  10. Mamtani, R.
  11. Wu, C.
  12. Matsangou, M.
  13. Campbell, M.
  14. Petrylak, D.P.
Revista:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Ano de publicación: 2023

Tipo: Artigo

DOI: 10.1016/J.ANNONC.2023.08.016 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus